Mitch Dowsett
Impact in
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
Papers in
- Co-authors
- Ian E. Smith (88 shared papers)Jack Cuzick (74 shared papers)Anthony Howell (45 shared papers)John Forbes (23 shared papers)Janine Salter (78 shared papers)Elizabeth Folkerd (69 shared papers)Ivana Šestak (62 shared papers)Giuseppe Viale (20 shared papers)
- Journals
- Journal of Clinical Oncology (82 papers)Cancer Research (81 papers)British Journal of Cancer (60 papers)Breast Cancer Research and Treatment (50 papers)Breast Cancer Research (46 papers)
- Partner nations
- United KingdomUnited StatesAustralia
In The Last Decade
Mitch Dowsett
776 papers receiving 60.1k citations
Mitch Dowsett's Hit Papers
Peers
Comparison fields: 5 of 181
- Cancer Research 21.1k
- Oncology 24.7k
- Genetics 18.0k
- Pulmonary and Respiratory Medicine 10.5k
- Endocrinology, Diabetes and Metabolism 4.1k
Countries citing papers authored by Mitch Dowsett
This map shows the geographic impact of Mitch Dowsett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitch Dowsett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitch Dowsett more than expected).
Fields of papers citing papers by Mitch Dowsett
This network shows the impact of papers produced by Mitch Dowsett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitch Dowsett. The network helps show where Mitch Dowsett may publish in the future.
Co-authors
The 25 scholars most cited alongside Mitch Dowsett, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 797 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update Hit paper breakdown → | 2013 | 3157 |
| 2 | Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Hit paper breakdown → | 2005 | 1794 |
| 3 | Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Hit paper breakdown → | 2018 | 1634 |
| 4 | Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update Hit paper breakdown → | 2013 | 1349 |
| 5 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Hit paper breakdown → | 2010 | 1172 |
| 6 | 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years Hit paper breakdown → | 2017 | 1138 |
| 7 | Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Hit paper breakdown → | 2018 | 1068 |
| 8 | Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update Hit paper breakdown → | 2020 | 920 |
| 9 | Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer Hit paper breakdown → | 2015 | 847 |
| 10 | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Hit paper breakdown → | 2017 | 724 |
| 11 | Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial Hit paper breakdown → | 1998 | 718 |
| 12 | Aromatase Inhibitors in Breast Cancer Hit paper breakdown → | 2003 | 715 |
| 13 | A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. Hit paper breakdown → | 1995 | 699 |
| 14 | Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven Hit paper breakdown → | 2008 | 699 |
| 15 | Proliferation Marker Ki-67 in Early Breast Cancer Hit paper breakdown → | 2005 | 673 |
| 16 | Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men Hit paper breakdown → | 2007 | 615 |
| 17 | Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen Hit paper breakdown → | 2009 | 609 |
| 18 | Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial Hit paper breakdown → | 2005 | 583 |
| 19 | Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study Hit paper breakdown → | 2010 | 570 |
| 20 | Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer Hit paper breakdown → | 2011 | 569 |
About Mitch Dowsett
Mitch Dowsett is a scholar working on Genetics, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 797 papers that have together received 62.3k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (388 papers), Breast Cancer Treatment Studies (224 papers), HER2/EGFR in Cancer Research (127 papers), Advanced Breast Cancer Therapies (91 papers), Cancer Risks and Factors (60 papers), Cancer Treatment and Pharmacology (43 papers), Hormonal and reproductive studies (39 papers) and Monoclonal and Polyclonal Antibodies Research (32 papers). The work is most often cited by research in Cancer Research (21.1k citations), Oncology (24.7k citations), Genetics (18.0k citations), Pulmonary and Respiratory Medicine (10.5k citations) and Endocrinology, Diabetes and Metabolism (4.1k citations). Mitch Dowsett has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Ian E. Smith, Jack Cuzick, Anthony Howell, John Forbes, Janine Salter, Elizabeth Folkerd, Ivana Šestak, Giuseppe Viale, Simone Detre and Lisa M. McShane. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, British Journal of Cancer, Breast Cancer Research and Treatment and Breast Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.